Why the study?
To evaluate patient preferences for ERA plus PDE5i combination therapies in pulmonary arterial hypertension, including the potential benefits of single tablet combination therapy in reducing pill burden and improving adherence.
Does a single tablet combination therapy (STCT) of an endothelin receptor antagonist (ERA) and phosphodiesterase-5 inhibitor (PDE5i) improve patient preference and perceived adherence compared to loose-dose combination regimens in adults with pulmonary arterial hypertension?
Does a single tablet combination therapy (STCT) of an endothelin receptor antagonist (ERA) and phosphodiesterase-5 inhibitor (PDE5i) improve patient preference and perceived adherence compared to loose-dose combination regimens in adults with pulmonary arterial hypertension?
Answers are grounded in this paper and cite their sources.
Among US patients with pulmonary arterial hypertension, simplified once-daily single-tablet combination therapy (ERA + PDE5i) is strongly preferred to reduce pill burden, provided that out-of-pocket costs remain low.
Background: To evaluate patient preferences for endothelin receptor antagonist (ERA) + phosphodiesterase-5 inhibitor (PDE5i) combination therapies in managing pulmonary arterial hypertension (PAH), including the potential benefits of a single tablet combination therapy (STCT) in reducing pill burden and improving adherence. Methods: An online survey was administered to 201 adult patients with PAH residing in the United States. Patients' preferences toward oral PAH therapies, including willingness to use double combination ERA+PDE5i therapy, were assessed using a discrete choice experiment (DCE). Results: Respondents were predominantly White (86.1%) and female (88.6%), with a median age of 59 years. Most were not employed (56.2%), and 38.3% reported a disability. At the time of the survey, 36.8% were on triple therapy (PDE5i + ERA + prostacyclin), 17.9% on dual therapy (PDE5i + ERA), and the remaining on other or no therapy. Out-of-pocket costs and dosing regimen were the top factors influencing therapy choice in the DCE, with patients preferring lower out-of-pocket costs and simpler dosing regimens. Regarding STCT, 83.1% believed it would reduce pill consumption, 68.7% thought it would decrease time spent managing prescriptions, and 34.8% and 39.3% anticipated improvements in treatment initiation and adherence, respectively. Conclusions: STCT offers potential benefits in reducing pill burden, improving convenience, and possibly facilitating treatment initiation and adherence. However, cost remains a significant factor influencing patient decision-making in PAH therapy in the United States. Addressing cost concerns may increase the acceptance of ERA + PDE5i therapies and STCT among patients with PAH.
No takes yet. Share an insight, caveat, or question.
Kolaitis et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: